2024

Birtle, A. J. et al. (2024) Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: Final results of the POUT trial. Journal of Clinical Oncology, (doi: 10.1200/jco.23.01659) (PMID:38350047) (Early Online Publication)

Fizazi, K. et al. (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30, (doi: 10.1038/s41591-024-02835-9)

Welisch, G., Keith, N. , Jones, R. and Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. Project Report. OSF. (doi: 10.17605/OSF.IO/243XN).

2023

Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2023) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, (Accepted for Publication)

Fizazi, K. et al. (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30, pp. 257-264. (doi: 10.1038/s41591-023-02704-x) (PMID:38049622) (PMCID:PMC10803259)

Conroy, S. et al. (2023) Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019. BJU International, 132(5), pp. 541-553. (doi: 10.1111/bju.16128) (PMID:37436368)

Critchlow, S. et al. (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, (doi: 10.2217/fon-2023-0372) (PMID:37529943) (Early Online Publication)

Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

Catto, J. W.F. et al. (2023) Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU International, 131(6), pp. 734-744. (doi: 10.1111/bju.15970) (PMID:36680312)

Mar, N. et al. (2023) Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma. Cancers, 15(11), 2978. (doi: 10.3390/cancers15112978) (PMID:37296940) (PMCID:PMC10251876)

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24(5), pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, pp. 178-215. (doi: 10.1016/j.ejca.2023.02.018) (PMID:37003085)

Lees, J. S. , Elyan, B. M.P., Hermann, S. M., Lang, N. N. , Jones, R. J. and Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38(5), pp. 1071-1079. (doi: 10.1093/ndt/gfac011) (PMID:35090037) (PMCID:PMC10157781)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. European Urology, 83(3), pp. 267-293. (doi: 10.1016/j.eururo.2022.11.002) (PMID:36494221)

Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167) (PMCID:PMC10087532)

Gravestock, P. et al. (2023) Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research, 2, 49. (doi: 10.3310/nihropenres.13284.2) (PMID:37035713) (PMCID:PMC7614403)

Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)

2022

Crabb, S. J. et al. (2022) Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. European Urology, 82(5), pp. 512-515. (doi: 10.1016/j.eururo.2022.05.019) (PMID:35688662)

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 127(6), pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7) (PMID:35739300) (PMCID:PMC9470559)

Annese, V. F. , Hu, C. , Barrett, M. P. , Jones, R. and Cumming, D. R. S. (2022) A CMOS-based multi-omics detection platform for simultaneous quantification of proteolytically active prostate specific antigen and glutamate in urine. IEEE Sensors Journal, 22(19), pp. 18870-18877. (doi: 10.1109/JSEN.2022.3198282)

Hanna, C.R. , Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P. , Boyd, K.A. and Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34(9), pp. 554-560. (doi: 10.1016/j.clon.2022.03.012) (PMID:35370039)

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), pp. 422-434. (doi: 10.1002/ijc.34018) (PMID:35411939)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6(4), pkac043. (doi: 10.1093/jncics/pkac043) (PMID:35877084) (PMCID:PMC9338456)

Wilson, B. E. et al. (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 170, pp. 296-304. (doi: 10.1016/j.ejca.2022.03.042) (PMID:35568679)

Gillessen, S. et al. (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. European Urology, 82(1), pp. 115-141. (doi: 10.1016/j.eururo.2022.04.002) (PMID:35450732)

Turco, F. et al. (2022) What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), pp. 6-11. (doi: 10.1016/j.eururo.2022.02.010) (PMID:35393158) (PMCID:PMC8849852)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19(6), e1003998. (doi: 10.1371/journal.pmed.1003998) (PMID:35671327) (PMCID:PMC9173627)

Clarke, C. S. et al. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17(6), e0269192. (doi: 10.1371/journal.pone.0269192) (PMID:35653395) (PMCID:PMC9162346)

Hussain, S. A. et al. (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncology, 23(5), pp. 650-658. (doi: 10.1016/S1470-2045(22)00158-9) (PMID:35421369)

Dunlop, E. et al. (2022) What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 30(4), pp. 3141-3150. (doi: 10.1007/s00520-021-06724-6) (PMID:34878587) (PMCID:PMC8857102)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5) (PMID:34953525) (PMCID:PMC8811484)

Mueller, T. et al. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28(1), p. 14604582221077055. (doi: 10.1177/14604582221077055) (PMID:35195024)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, 757. (doi: 10.1186/s13063-022-06680-4) (PMID:36068599) (PMCID:PMC9449272)

2021

Halabi, S. et al. (2021) Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal, 19(3), pp. 64-72. (doi: 10.52733/kcj19n3-a1)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Welisch, G. et al. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? Project Report. OSF. (doi: 10.17605/OSF.IO/KWHQF).

Armstrong, A. J. et al. (2021) Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma. Clinical Cancer Research, 27(12), pp. 3317-3328. (doi: 10.1158/1078-0432.CCR-20-4504) (PMID:33593885)

Powles, T. et al. (2021) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature Medicine, 27(5), pp. 793-801. (doi: 10.1038/s41591-021-01317-6) (PMID:33941921)

Hanna, C. , Lemmon, E., Ennis, H., Jones, R. , Hay, J., Halliday, R., Clark, S., Morris, E. and Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6(1), 10. (doi: 10.23889/ijpds.v6i1.1654) (PMID:34007905) (PMCID:PMC8111382)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Hanna, C. R. , Boyd, K. A. and Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, 36. (doi: 10.1186/s12961-020-00658-x) (PMID:33706777) (PMCID:PMC7953786)

Annese, V. F. et al. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, 21. (doi: 10.1038/s41378-021-00243-4) (PMID:34567735) (PMCID:PMC8433377)

Crabb, S. J. et al. (2021) Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). Journal of Clinical Oncology, 39(3), pp. 190-201. (doi: 10.1200/JCO.20.01576) (PMID:33326257)

Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)

2020

Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)

Hall, P. E. et al. (2020) Radiological response heterogeneity is of prognostic significance in metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. European Urology Focus, 6(5), pp. 999-1005. (doi: 10.1016/j.euf.2019.01.010) (PMID:30738795)

Pritchard, J. J.G., Hamilton, G., Hurst, C. D., Fraser, S., Orange, C., Knowles, M. A., Jones, R. J. , Leung, H. Y. and Iwata, T. (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38(9), 731.e1-737.e10. (doi: 10.1016/j.urolonc.2020.05.012) (PMID:32532529)

Jones, R. et al. (2020) A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International, 126(2), pp. 292-299. (doi: 10.1111/bju.15096) (PMID:32336008)

Lewis, R., Todd, R., Newton, M., Jones, R. J. , Wilson, C., Donovan, J. L., Bryan, R. T., Birtle, A. and Hall, E. (2020) The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials, 21, 629. (doi: 10.1186/s13063-020-04559-w) (PMID:32641097) (PMCID:PMC7346417)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Rana, D. et al. (2020) Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting. EUHEA 2020, Online, 9 July 2020.

Hanna, C. R. , Gatting, L. P., Boyd, K. A. , Robb, K. A. and Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, 486. (doi: 10.1186/s13063-020-04425-9) (PMID:32503612) (PMCID:PMC7275320)

Baillie, K. et al. (2020) Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 29(6), pp. 653-663. (doi: 10.1002/pds.4998) (PMID:32316077)

Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)

Birtle, A. et al. (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 395(10232), pp. 1268-1277. (doi: 10.1016/S0140-6736(20)30415-3) (PMID:32145825) (PMCID:PMC7181180)

Witjes, J. A. et al. (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees. European Urology, 77(2), pp. 223-250. (doi: 10.1016/j.eururo.2019.09.035) (PMID:31753752)

Mateo, J. et al. (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 21(1), pp. 162-174. (doi: 10.1016/S1470-2045(19)30684-9) (PMID:31806540) (PMCID:PMC6941219)

2019

Clark, E. et al. (2019) Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 9(12), e034708. (doi: 10.1136/bmjopen-2019-034708) (PMID:31857319) (PMCID:PMC6937062)

Paterson, C. et al. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57(10), pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300) (PMID:31672256)

Clarke, N. W. et al. (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30(123), pp. 1992-2003. (doi: 10.1093/annonc/mdz396) (PMID:31560068) (PMCID:PMC6938598)

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

Horwich, A. et al. (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 30(11), pp. 1697-1727. (doi: 10.1093/annonc/mdz296) (PMID:31740927) (PMCID:PMC7360152)

Hasan, M. N., Rouprêt, M., Keeley, F., Cracco, C., Jones, R. , Straub, M., Traxer, O., Osther, P. J. S. and Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology, 37(11), pp. 2289-2296. (doi: 10.1007/s00345-019-02739-1) (PMID:30944969) (PMCID:PMC6825637)

Jung, H., Giusti, G., Fajkovic, H., Herrmann, T., Jones, R. , Straub, M., Baard, J., Osther, P. J. S. and Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018: aspects of treatment. World Journal of Urology, 37(11), pp. 2279-2287. (doi: 10.1007/s00345-019-02811-w) (PMID:31123852) (PMCID:PMC6825640)

Attard, G. et al. (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate formetastatic castration-resistant prostate Cancer: a randomized, open-label phase 2 study. JAMA Oncology, 5(8), pp. 1159-1167. (doi: 10.1001/jamaoncol.2019.1011) (PMID:31246234) (PMCID:PMC6604092)

Neves, K. B. , Rios, F. J. , Jones, R. , Evans, T. R. J. , Montezano, A. C. and Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115(5), pp. 978-988. (doi: 10.1093/cvr/cvz021) (PMID:30753341) (PMCID:PMC6452312)

Anderson, R. L. et al. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), pp. 185-204. (doi: 10.1038/s41571-018-0134-8) (PMID:30514977) (PMCID:PMC7136167)

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R. and Protheroe, A. (2018) From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. European Urology Oncology, 1(6), pp. 486-500. (doi: 10.1016/j.euo.2018.05.011) (PMID:31158093)

Parker, C. C. et al. (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), pp. 2353-2366. (doi: 10.1016/S0140-6736(18)32486-3) (PMID:30355464) (PMCID:PMC6269599)

Woods, B. S. et al. (2018) Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology, 1(6), pp. 449-458. (doi: 10.1016/j.euo.2018.06.004) (PMID:31158087) (PMCID:PMC6692495)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169) (PMCID:PMC5961425)

Schmidinger, M., Danesi, R., Jones, R. , McDermott, R., Pyle, L., Rini, B. and Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14(9), pp. 861-875. (doi: 10.2217/fon-2017-0455) (PMID:29264944)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)

Jones, R. J. (2018) Neoadjuvant vs. adjuvant chemotherapy: which is right? In: Soria, F. and Gontero, P. (eds.) Treating Urothelial Bladder Cancer. Springer: Cham, pp. 75-81. ISBN 9783319785585 (doi: 10.1007/978-3-319-78559-2_10)

Jones, R. J. (2018) The role of medical oncologist. In: Soria, F. and Gontero, P. (eds.) Treating Urothelial Bladder Cancer. Springer: Cham, pp. 119-122. ISBN 9783319785585 (doi: 10.1007/978-3-319-78559-2_15)

2017

Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131(21), pp. 2627-2642. (doi: 10.1042/CS20160894) (PMID:29079639)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120(5B), E64-E79. (doi: 10.1111/bju.13854) (PMID:28346770)

Crabb, S. J. et al. (2017) ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 35(5), pp. 599-607. (doi: 10.1007/s10637-017-0433-4) (PMID:28144789) (PMCID:PMC5613074)

Escudier, B. et al. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12(5), pp. 655-661. (doi: 10.1007/s11523-017-0525-2) (PMID:28798986)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Gore, M. E., Jones, R. J. , Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P. and Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119(6), pp. 846-853. (doi: 10.1111/bju.13740) (PMID:27981711)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

Jones, R. J. and Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi: 10.1016/j.plabm.2016.04.004) (PMID:28856218) (PMCID:PMC5575409)

Powles, T. et al. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35(1), pp. 48-55. (doi: 10.1200/JCO.2015.66.3468) (PMID:28034079)

2016

Reza, M. et al. (2016) Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus, 2(5), pp. 547-552. (doi: 10.1016/j.euf.2016.01.005) (PMID:28723521)

Powles, T. et al. (2016) Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncology, 2(10), pp. 1303-1309. (doi: 10.1001/jamaoncol.2016.1197) (PMID:27254750)

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi: 10.1007/s40291-016-0196-1) (PMID:27020582)

Davda, R., Hughes, S., Jones, R. , Crabb, S.J., Troup, J. and Payne, H. (2016) Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer. Clinical Oncology, 28(6), pp. 376-385. (doi: 10.1016/j.clon.2016.01.006) (PMID:26874654)

Armstrong, A. J. et al. (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17(3), pp. 378-388. (doi: 10.1016/S1470-2045(15)00515-X) (PMID:26794930)

Wagstaff, J., Jones, R. , Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., Brown, J. and Buchan, S. (2016) Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology, 27(1), pp. 159-165. (doi: 10.1093/annonc/mdv504) (PMID:26489444) (PMCID:PMC4684158)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi: 10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

Fulton, B. and Jones, R. J. (2016) Combination treatment strategies with docetaxel in patients with metastatic prostate. In: Balaji, K.C. (ed.) Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Springer: Cham, pp. 93-105. ISBN 9783319313399 (doi: 10.1007/978-3-319-31341-2_7)

James, N. D. et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform-randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. (doi: 10.1016/S0140-6736(15)01037-5) (PMID:26719232)

Powles, T. et al. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27(5), pp. 880-886. (doi: 10.1093/annonc/mdw014) (PMID:26802156)

Roseweir, A. K. , Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J. and Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, p. 229. (doi: 10.1186/s12885-016-2254-9) (PMID:26984511) (PMCID:PMC4794832)

2015

Bahl, A. et al. (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU International, 116(6), pp. 880-887. (doi: 10.1111/bju.13069) (PMID:25639506)

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi: 10.2217/fon.15.228) (PMID:26436556)

Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J. , Mazurkiewicz, M., Temple, G., Dressler, H. and Bondarenko, I. (2015) A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), pp. 1140-1147. (doi: 10.1038/bjc.2015.313) (PMID:26448178) (PMCID:PMC4647871)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi: 10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Mateo, J. et al. (2015) DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), pp. 1697-1708. (doi: 10.1056/NEJMoa1506859) (PMID:26510020)

Huddart, R.A., Jones, R. and Choudhury, A. (2015) A new dawn for bladder cancer? Recommendations from the national institute for health and care excellence (NICE) on managing bladder cancer. Clinical Oncology, 27(7), pp. 380-381. (doi: 10.1016/j.clon.2015.03.008) (PMID:25869257)

James, N. D. et al. (2015) Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 67(6), pp. 1028-1038. (doi: 10.1016/j.eururo.2014.09.032) (PMID:25301760)

Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi: 10.1007/s10637-015-0235-5) (PMID:25920479)

Geldart, T. et al. (2015) SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology, 67(4), pp. 599-602. (doi: 10.1016/j.eururo.2014.11.003)

Fizazi, K. et al. (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology, 33(7), pp. 723-731. (doi: 10.1200/JCO.2014.56.5119) (PMID:25624429)

Saad, F. et al. (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, 16(3), pp. 338-348. (doi: 10.1016/S1470-2045(15)70027-6) (PMID:25701170)

Jones, R. J. (2015) Making trials work in practice: please mind the gap. European Urology, 67(2), pp. 250-251. (doi: 10.1016/j.eururo.2014.10.006)

Harris, R., Oake, K., Hawkins, R. E., Jones, R. J. , Powles, T. and Montgomery, D. A. (2015) Patient needs in advanced renal cell carcinoma: what are patients’ priorities and how well are we meeting them. Patient Experience Journal, 2(2), 18.

Payne, H., Davda, R., Jones, R. , Crabb, S., Troup, J. and Hughes, S. (2015) Advances in advanced prostate cancer - the continuing journey. BJU International, 118(1), pp. 17-19. (doi: 10.1111/bju.13350) (PMID:26456636)

2014

Muinonen-Martin, A. J. et al. (2014) Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biology, 12(10), e1001966. (doi: 10.1371/journal.pbio.1001966) (PMID:25313567) (PMCID:PMC4196730)

Loriot, Y. et al. (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs, 32(5), pp. 995-1004. (doi: 10.1007/s10637-014-0101-x)

Jones, R. J. (2014) Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence. European Urology, 66(3), pp. 466-467. (doi: 10.1016/j.eururo.2013.12.053)

Powles, T. et al. (2014) A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. European Journal of Cancer, 50(12), pp. 2057-64. (doi: 10.1016/j.ejca.2014.04.021)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi: 10.1002/bjs.9510)

Molife, L. .R. et al. (2014) Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 10(2), pp. 219-231. (doi: 10.2217/fon.13.250)

Michaelson, M. D. et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology, 32(2), pp. 76-82. (doi: 10.1200/JCO.2012.48.5268)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi: 10.1038/bjc.2014.316)

2013

Eisen, T. et al. (2013) Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 31(5), pp. 1283-1293. (doi: 10.1007/s10637-013-9962-7)

Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi: 10.1053/j.seminoncol.2013.05.012)

Ford, J. et al. (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29), pp. 1-386. (doi: 10.3310/hta17290)

Jones, R. (2013) Urological medical oncology: land of opportunity. Future Oncology, 9(2), pp. 149-152. (doi: 10.2217/FON.12.176)

Ford, J.A., Jones, R. , Elders, A., Mulatero, C., Royle, P., Sharma, P., Stewart, F., Todd, R. and Mowatt, G. (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. European Journal of Cancer, 49(2), pp. 416-430. (doi: 10.1016/j.ejca.2012.07.016)

Jones, R. et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs, 31(4), pp. 1001-1007. (doi: 10.1007/s10637-013-9926-y)

Motzer, R.J. et al. (2013) Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), pp. 722-731. (doi: 10.1056/NEJMoa1303989)

Salazar, R. et al. (2013) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 70(5), pp. 673-681. (doi: 10.1007/s00280-012-1951-6)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi: 10.1186/1471-2490-13-26)

2012

Logothetis, C.J. et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13(12), pp. 1210-1217. (doi: 10.1016/S1470-2045(12)70473-4)

Olmos, D. et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, 13(11), pp. 1114-1124. (doi: 10.1016/S1470-2045(12)70372-8)

Powles, T. et al. (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European Journal of Cancer, 48(17), pp. 3171-3176. (doi: 10.1016/j.ejca.2012.05.022)

Fizazi, K. et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), pp. 983-992. (doi: 10.1016/S1470-2045(12)70379-0)

Ford, J.A., Mowatt, G. and Jones, R.J. (2012) Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Review of Clinical Pharmacology, 5(3), pp. 271-279. (doi: 10.1586/ecp.12.21)

Kaye, S. et al. (2012) Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer, 106(11), pp. 1728-1734. (doi: 10.1038/bjc.2012.158)

Leach, M.O. et al. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 22(7), pp. 1451-1464. (doi: 10.1007/s00330-012-2446-x)

Qayyum, T. et al. (2012) Abstracts of the 10th International Kidney Cancer Symposium: The role of Src kinase in renal cell cancer. BJU International, 109(S5), p. 10. (doi: 10.1111/j.1464-410X.2012.11171.x)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi: 10.1038/bjc.2012.314)

2011

Harrington, J.A. and Jones, R.J. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer, 47(14), pp. 2133-2142. (doi: 10.1016/j.ejca.2011.04.036)

de Bono, J.S. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), pp. 1995-2005. (doi: 10.1056/NEJMoa1014618)

Le Pechoux, C. et al. (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), pp. 1154-1163. (doi: 10.1093/annonc/mdq576)

Powles, T., Chowdhury, S., Jones, R. , Mantle, M., Nathan, P., Bex, A., Lim, L. and Hutson, T. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), pp. 741-745. (doi: 10.1038/sj.bjc.6606061)

Jones, R.J., Green, T.P. and Elvin, P. (2011) Discovery and development of drugs targeting tumour invasion and metastasis. In: Lyden, D., Welch, D.R. and Psaila, B. (eds.) Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press, pp. 600-611. ISBN 9780521887212

2010

Powles, T., Jones, R.J., Chowdhury, S., Shamash, J., Mantle, M., Lim, L. and Hutson, T. (2010) The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? BJU International, 106(4), pp. 453-457. (doi: 10.1111/j.1464-410X.2010.09466.x)

2009

Paterson, C. and Jones, R.J. (2009) Tumour Flare during Interruption of Temsirolimus Treatment for Metastatic Renal Cell Cancer. Clinical Oncology, 21(9), pp. 732-733. (doi: 10.1016/j.clon.2009.07.006)

Jones, R. J. et al. (2009) Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment, 114(2), pp. 211-221. (doi: 10.1007/s10549-008-9997-1)

2008

Jones, R., Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi: 10.1007/s00280-007-0486-8)

Twelves, C., Trigo, J. M., Jones, R. , De Rosa, F., Rakhit, A., Fettner, S., Wright, T. and Baselga, J. (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. European Journal of Cancer, 44(3), pp. 419-426. (doi: 10.1016/j.ejca.2007.12.011)

Jones, R.J., Boyce, T., Fennell, M., Jacobs, V., Pinto, F., Duffield, E., Clack, G., Green, T., Kelly, J. and Robertson, J. (2008) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology, 61(1), pp. 23-32. (doi: 10.1007/s00280-007-0440-9)

2007

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R., Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi: 10.1158/1078-0432.CCR-06-1627)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

2003

Glen, H. and Jones, R.J. (2003) 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003. Breast Cancer Research, 5(4), pp. 198-201. (doi: 10.1186/bcr611)

2002

Jones, R. , Avizienyte, E., Wyke, A., Owens, D., Brunton, V. and Frame, M. (2002) Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM1 2C human colorectal cancer cells. British Journal of Cancer, 87(10), pp. 1128-1135. (doi: 10.1038/sj.bjc.6600594)

Avizienyte, E., Wyke, A., Jones, R. , McLean, G., Westhoff, M., Brunton, V. and Frame, M. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nature Cell Biology, 4(8), pp. 632-638. (doi: 10.1038/ncb829)

Jones, R. and Twelves, C. (2002) Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Expert Review of Anticancer Therapy, 2(1), pp. 13-22. (doi: 10.1586/14737140.2.1.13)

2001

Twelves, C. and Jones, R. (2001) Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy, 2(9), pp. 1495-1505. (doi: 10.1517/14656566.2.9.1495)

Articles

Birtle, A. J. et al. (2024) Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: Final results of the POUT trial. Journal of Clinical Oncology, (doi: 10.1200/jco.23.01659) (PMID:38350047) (Early Online Publication)

Fizazi, K. et al. (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30, (doi: 10.1038/s41591-024-02835-9)

Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2023) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, (Accepted for Publication)

Fizazi, K. et al. (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30, pp. 257-264. (doi: 10.1038/s41591-023-02704-x) (PMID:38049622) (PMCID:PMC10803259)

Conroy, S. et al. (2023) Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019. BJU International, 132(5), pp. 541-553. (doi: 10.1111/bju.16128) (PMID:37436368)

Critchlow, S. et al. (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, (doi: 10.2217/fon-2023-0372) (PMID:37529943) (Early Online Publication)

Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

Catto, J. W.F. et al. (2023) Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU International, 131(6), pp. 734-744. (doi: 10.1111/bju.15970) (PMID:36680312)

Mar, N. et al. (2023) Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma. Cancers, 15(11), 2978. (doi: 10.3390/cancers15112978) (PMID:37296940) (PMCID:PMC10251876)

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24(5), pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, pp. 178-215. (doi: 10.1016/j.ejca.2023.02.018) (PMID:37003085)

Lees, J. S. , Elyan, B. M.P., Hermann, S. M., Lang, N. N. , Jones, R. J. and Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38(5), pp. 1071-1079. (doi: 10.1093/ndt/gfac011) (PMID:35090037) (PMCID:PMC10157781)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. European Urology, 83(3), pp. 267-293. (doi: 10.1016/j.eururo.2022.11.002) (PMID:36494221)

Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167) (PMCID:PMC10087532)

Gravestock, P. et al. (2023) Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research, 2, 49. (doi: 10.3310/nihropenres.13284.2) (PMID:37035713) (PMCID:PMC7614403)

Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)

Crabb, S. J. et al. (2022) Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. European Urology, 82(5), pp. 512-515. (doi: 10.1016/j.eururo.2022.05.019) (PMID:35688662)

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 127(6), pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7) (PMID:35739300) (PMCID:PMC9470559)

Annese, V. F. , Hu, C. , Barrett, M. P. , Jones, R. and Cumming, D. R. S. (2022) A CMOS-based multi-omics detection platform for simultaneous quantification of proteolytically active prostate specific antigen and glutamate in urine. IEEE Sensors Journal, 22(19), pp. 18870-18877. (doi: 10.1109/JSEN.2022.3198282)

Hanna, C.R. , Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P. , Boyd, K.A. and Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34(9), pp. 554-560. (doi: 10.1016/j.clon.2022.03.012) (PMID:35370039)

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), pp. 422-434. (doi: 10.1002/ijc.34018) (PMID:35411939)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6(4), pkac043. (doi: 10.1093/jncics/pkac043) (PMID:35877084) (PMCID:PMC9338456)

Wilson, B. E. et al. (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 170, pp. 296-304. (doi: 10.1016/j.ejca.2022.03.042) (PMID:35568679)

Gillessen, S. et al. (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. European Urology, 82(1), pp. 115-141. (doi: 10.1016/j.eururo.2022.04.002) (PMID:35450732)

Turco, F. et al. (2022) What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), pp. 6-11. (doi: 10.1016/j.eururo.2022.02.010) (PMID:35393158) (PMCID:PMC8849852)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19(6), e1003998. (doi: 10.1371/journal.pmed.1003998) (PMID:35671327) (PMCID:PMC9173627)

Clarke, C. S. et al. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17(6), e0269192. (doi: 10.1371/journal.pone.0269192) (PMID:35653395) (PMCID:PMC9162346)

Hussain, S. A. et al. (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncology, 23(5), pp. 650-658. (doi: 10.1016/S1470-2045(22)00158-9) (PMID:35421369)

Dunlop, E. et al. (2022) What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 30(4), pp. 3141-3150. (doi: 10.1007/s00520-021-06724-6) (PMID:34878587) (PMCID:PMC8857102)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5) (PMID:34953525) (PMCID:PMC8811484)

Mueller, T. et al. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28(1), p. 14604582221077055. (doi: 10.1177/14604582221077055) (PMID:35195024)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, 757. (doi: 10.1186/s13063-022-06680-4) (PMID:36068599) (PMCID:PMC9449272)

Halabi, S. et al. (2021) Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal, 19(3), pp. 64-72. (doi: 10.52733/kcj19n3-a1)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Armstrong, A. J. et al. (2021) Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma. Clinical Cancer Research, 27(12), pp. 3317-3328. (doi: 10.1158/1078-0432.CCR-20-4504) (PMID:33593885)

Powles, T. et al. (2021) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature Medicine, 27(5), pp. 793-801. (doi: 10.1038/s41591-021-01317-6) (PMID:33941921)

Hanna, C. , Lemmon, E., Ennis, H., Jones, R. , Hay, J., Halliday, R., Clark, S., Morris, E. and Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6(1), 10. (doi: 10.23889/ijpds.v6i1.1654) (PMID:34007905) (PMCID:PMC8111382)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Hanna, C. R. , Boyd, K. A. and Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, 36. (doi: 10.1186/s12961-020-00658-x) (PMID:33706777) (PMCID:PMC7953786)

Annese, V. F. et al. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, 21. (doi: 10.1038/s41378-021-00243-4) (PMID:34567735) (PMCID:PMC8433377)

Crabb, S. J. et al. (2021) Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). Journal of Clinical Oncology, 39(3), pp. 190-201. (doi: 10.1200/JCO.20.01576) (PMID:33326257)

Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)

Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)

Hall, P. E. et al. (2020) Radiological response heterogeneity is of prognostic significance in metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. European Urology Focus, 6(5), pp. 999-1005. (doi: 10.1016/j.euf.2019.01.010) (PMID:30738795)

Pritchard, J. J.G., Hamilton, G., Hurst, C. D., Fraser, S., Orange, C., Knowles, M. A., Jones, R. J. , Leung, H. Y. and Iwata, T. (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38(9), 731.e1-737.e10. (doi: 10.1016/j.urolonc.2020.05.012) (PMID:32532529)

Jones, R. et al. (2020) A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International, 126(2), pp. 292-299. (doi: 10.1111/bju.15096) (PMID:32336008)

Lewis, R., Todd, R., Newton, M., Jones, R. J. , Wilson, C., Donovan, J. L., Bryan, R. T., Birtle, A. and Hall, E. (2020) The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials, 21, 629. (doi: 10.1186/s13063-020-04559-w) (PMID:32641097) (PMCID:PMC7346417)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Hanna, C. R. , Gatting, L. P., Boyd, K. A. , Robb, K. A. and Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, 486. (doi: 10.1186/s13063-020-04425-9) (PMID:32503612) (PMCID:PMC7275320)

Baillie, K. et al. (2020) Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 29(6), pp. 653-663. (doi: 10.1002/pds.4998) (PMID:32316077)

Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)

Birtle, A. et al. (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 395(10232), pp. 1268-1277. (doi: 10.1016/S0140-6736(20)30415-3) (PMID:32145825) (PMCID:PMC7181180)

Witjes, J. A. et al. (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees. European Urology, 77(2), pp. 223-250. (doi: 10.1016/j.eururo.2019.09.035) (PMID:31753752)

Mateo, J. et al. (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 21(1), pp. 162-174. (doi: 10.1016/S1470-2045(19)30684-9) (PMID:31806540) (PMCID:PMC6941219)

Clark, E. et al. (2019) Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 9(12), e034708. (doi: 10.1136/bmjopen-2019-034708) (PMID:31857319) (PMCID:PMC6937062)

Paterson, C. et al. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57(10), pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300) (PMID:31672256)

Clarke, N. W. et al. (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30(123), pp. 1992-2003. (doi: 10.1093/annonc/mdz396) (PMID:31560068) (PMCID:PMC6938598)

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76(6), pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006) (PMID:31447077)

Horwich, A. et al. (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 30(11), pp. 1697-1727. (doi: 10.1093/annonc/mdz296) (PMID:31740927) (PMCID:PMC7360152)

Hasan, M. N., Rouprêt, M., Keeley, F., Cracco, C., Jones, R. , Straub, M., Traxer, O., Osther, P. J. S. and Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology, 37(11), pp. 2289-2296. (doi: 10.1007/s00345-019-02739-1) (PMID:30944969) (PMCID:PMC6825637)

Jung, H., Giusti, G., Fajkovic, H., Herrmann, T., Jones, R. , Straub, M., Baard, J., Osther, P. J. S. and Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018: aspects of treatment. World Journal of Urology, 37(11), pp. 2279-2287. (doi: 10.1007/s00345-019-02811-w) (PMID:31123852) (PMCID:PMC6825640)

Attard, G. et al. (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate formetastatic castration-resistant prostate Cancer: a randomized, open-label phase 2 study. JAMA Oncology, 5(8), pp. 1159-1167. (doi: 10.1001/jamaoncol.2019.1011) (PMID:31246234) (PMCID:PMC6604092)

Neves, K. B. , Rios, F. J. , Jones, R. , Evans, T. R. J. , Montezano, A. C. and Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115(5), pp. 978-988. (doi: 10.1093/cvr/cvz021) (PMID:30753341) (PMCID:PMC6452312)

Anderson, R. L. et al. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), pp. 185-204. (doi: 10.1038/s41571-018-0134-8) (PMID:30514977) (PMCID:PMC7136167)

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R. and Protheroe, A. (2018) From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. European Urology Oncology, 1(6), pp. 486-500. (doi: 10.1016/j.euo.2018.05.011) (PMID:31158093)

Parker, C. C. et al. (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), pp. 2353-2366. (doi: 10.1016/S0140-6736(18)32486-3) (PMID:30355464) (PMCID:PMC6269599)

Woods, B. S. et al. (2018) Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology, 1(6), pp. 449-458. (doi: 10.1016/j.euo.2018.06.004) (PMID:31158087) (PMCID:PMC6692495)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi: 10.1093/annonc/mdy072) (PMID:29529169) (PMCID:PMC5961425)

Schmidinger, M., Danesi, R., Jones, R. , McDermott, R., Pyle, L., Rini, B. and Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14(9), pp. 861-875. (doi: 10.2217/fon-2017-0455) (PMID:29264944)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131(21), pp. 2627-2642. (doi: 10.1042/CS20160894) (PMID:29079639)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120(5B), E64-E79. (doi: 10.1111/bju.13854) (PMID:28346770)

Crabb, S. J. et al. (2017) ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 35(5), pp. 599-607. (doi: 10.1007/s10637-017-0433-4) (PMID:28144789) (PMCID:PMC5613074)

Escudier, B. et al. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12(5), pp. 655-661. (doi: 10.1007/s11523-017-0525-2) (PMID:28798986)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi: 10.1056/NEJMoa1702900) (PMID:28578639)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Gore, M. E., Jones, R. J. , Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P. and Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119(6), pp. 846-853. (doi: 10.1111/bju.13740) (PMID:27981711)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677) (PMID:28300506)

Jones, R. J. and Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi: 10.1016/j.plabm.2016.04.004) (PMID:28856218) (PMCID:PMC5575409)

Powles, T. et al. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35(1), pp. 48-55. (doi: 10.1200/JCO.2015.66.3468) (PMID:28034079)

Reza, M. et al. (2016) Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus, 2(5), pp. 547-552. (doi: 10.1016/j.euf.2016.01.005) (PMID:28723521)

Powles, T. et al. (2016) Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncology, 2(10), pp. 1303-1309. (doi: 10.1001/jamaoncol.2016.1197) (PMID:27254750)

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi: 10.1007/s40291-016-0196-1) (PMID:27020582)

Davda, R., Hughes, S., Jones, R. , Crabb, S.J., Troup, J. and Payne, H. (2016) Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer. Clinical Oncology, 28(6), pp. 376-385. (doi: 10.1016/j.clon.2016.01.006) (PMID:26874654)

Armstrong, A. J. et al. (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17(3), pp. 378-388. (doi: 10.1016/S1470-2045(15)00515-X) (PMID:26794930)

Wagstaff, J., Jones, R. , Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., Brown, J. and Buchan, S. (2016) Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology, 27(1), pp. 159-165. (doi: 10.1093/annonc/mdv504) (PMID:26489444) (PMCID:PMC4684158)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi: 10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

James, N. D. et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform-randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. (doi: 10.1016/S0140-6736(15)01037-5) (PMID:26719232)

Powles, T. et al. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27(5), pp. 880-886. (doi: 10.1093/annonc/mdw014) (PMID:26802156)

Roseweir, A. K. , Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J. and Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, p. 229. (doi: 10.1186/s12885-016-2254-9) (PMID:26984511) (PMCID:PMC4794832)

Bahl, A. et al. (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU International, 116(6), pp. 880-887. (doi: 10.1111/bju.13069) (PMID:25639506)

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi: 10.2217/fon.15.228) (PMID:26436556)

Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J. , Mazurkiewicz, M., Temple, G., Dressler, H. and Bondarenko, I. (2015) A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), pp. 1140-1147. (doi: 10.1038/bjc.2015.313) (PMID:26448178) (PMCID:PMC4647871)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi: 10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Mateo, J. et al. (2015) DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), pp. 1697-1708. (doi: 10.1056/NEJMoa1506859) (PMID:26510020)

Huddart, R.A., Jones, R. and Choudhury, A. (2015) A new dawn for bladder cancer? Recommendations from the national institute for health and care excellence (NICE) on managing bladder cancer. Clinical Oncology, 27(7), pp. 380-381. (doi: 10.1016/j.clon.2015.03.008) (PMID:25869257)

James, N. D. et al. (2015) Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 67(6), pp. 1028-1038. (doi: 10.1016/j.eururo.2014.09.032) (PMID:25301760)

Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi: 10.1007/s10637-015-0235-5) (PMID:25920479)

Geldart, T. et al. (2015) SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology, 67(4), pp. 599-602. (doi: 10.1016/j.eururo.2014.11.003)

Fizazi, K. et al. (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology, 33(7), pp. 723-731. (doi: 10.1200/JCO.2014.56.5119) (PMID:25624429)

Saad, F. et al. (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, 16(3), pp. 338-348. (doi: 10.1016/S1470-2045(15)70027-6) (PMID:25701170)

Jones, R. J. (2015) Making trials work in practice: please mind the gap. European Urology, 67(2), pp. 250-251. (doi: 10.1016/j.eururo.2014.10.006)

Harris, R., Oake, K., Hawkins, R. E., Jones, R. J. , Powles, T. and Montgomery, D. A. (2015) Patient needs in advanced renal cell carcinoma: what are patients’ priorities and how well are we meeting them. Patient Experience Journal, 2(2), 18.

Payne, H., Davda, R., Jones, R. , Crabb, S., Troup, J. and Hughes, S. (2015) Advances in advanced prostate cancer - the continuing journey. BJU International, 118(1), pp. 17-19. (doi: 10.1111/bju.13350) (PMID:26456636)

Muinonen-Martin, A. J. et al. (2014) Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biology, 12(10), e1001966. (doi: 10.1371/journal.pbio.1001966) (PMID:25313567) (PMCID:PMC4196730)

Loriot, Y. et al. (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs, 32(5), pp. 995-1004. (doi: 10.1007/s10637-014-0101-x)

Jones, R. J. (2014) Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence. European Urology, 66(3), pp. 466-467. (doi: 10.1016/j.eururo.2013.12.053)

Powles, T. et al. (2014) A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. European Journal of Cancer, 50(12), pp. 2057-64. (doi: 10.1016/j.ejca.2014.04.021)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi: 10.1002/bjs.9510)

Molife, L. .R. et al. (2014) Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 10(2), pp. 219-231. (doi: 10.2217/fon.13.250)

Michaelson, M. D. et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology, 32(2), pp. 76-82. (doi: 10.1200/JCO.2012.48.5268)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi: 10.1038/bjc.2014.316)

Eisen, T. et al. (2013) Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 31(5), pp. 1283-1293. (doi: 10.1007/s10637-013-9962-7)

Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi: 10.1053/j.seminoncol.2013.05.012)

Ford, J. et al. (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29), pp. 1-386. (doi: 10.3310/hta17290)

Jones, R. (2013) Urological medical oncology: land of opportunity. Future Oncology, 9(2), pp. 149-152. (doi: 10.2217/FON.12.176)

Ford, J.A., Jones, R. , Elders, A., Mulatero, C., Royle, P., Sharma, P., Stewart, F., Todd, R. and Mowatt, G. (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. European Journal of Cancer, 49(2), pp. 416-430. (doi: 10.1016/j.ejca.2012.07.016)

Jones, R. et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs, 31(4), pp. 1001-1007. (doi: 10.1007/s10637-013-9926-y)

Motzer, R.J. et al. (2013) Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), pp. 722-731. (doi: 10.1056/NEJMoa1303989)

Salazar, R. et al. (2013) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 70(5), pp. 673-681. (doi: 10.1007/s00280-012-1951-6)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi: 10.1186/1471-2490-13-26)

Logothetis, C.J. et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13(12), pp. 1210-1217. (doi: 10.1016/S1470-2045(12)70473-4)

Olmos, D. et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, 13(11), pp. 1114-1124. (doi: 10.1016/S1470-2045(12)70372-8)

Powles, T. et al. (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European Journal of Cancer, 48(17), pp. 3171-3176. (doi: 10.1016/j.ejca.2012.05.022)

Fizazi, K. et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), pp. 983-992. (doi: 10.1016/S1470-2045(12)70379-0)

Ford, J.A., Mowatt, G. and Jones, R.J. (2012) Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Review of Clinical Pharmacology, 5(3), pp. 271-279. (doi: 10.1586/ecp.12.21)

Kaye, S. et al. (2012) Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer, 106(11), pp. 1728-1734. (doi: 10.1038/bjc.2012.158)

Leach, M.O. et al. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 22(7), pp. 1451-1464. (doi: 10.1007/s00330-012-2446-x)

Qayyum, T. et al. (2012) Abstracts of the 10th International Kidney Cancer Symposium: The role of Src kinase in renal cell cancer. BJU International, 109(S5), p. 10. (doi: 10.1111/j.1464-410X.2012.11171.x)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi: 10.1038/bjc.2012.314)

Harrington, J.A. and Jones, R.J. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer, 47(14), pp. 2133-2142. (doi: 10.1016/j.ejca.2011.04.036)

de Bono, J.S. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), pp. 1995-2005. (doi: 10.1056/NEJMoa1014618)

Le Pechoux, C. et al. (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), pp. 1154-1163. (doi: 10.1093/annonc/mdq576)

Powles, T., Chowdhury, S., Jones, R. , Mantle, M., Nathan, P., Bex, A., Lim, L. and Hutson, T. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), pp. 741-745. (doi: 10.1038/sj.bjc.6606061)

Powles, T., Jones, R.J., Chowdhury, S., Shamash, J., Mantle, M., Lim, L. and Hutson, T. (2010) The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? BJU International, 106(4), pp. 453-457. (doi: 10.1111/j.1464-410X.2010.09466.x)

Paterson, C. and Jones, R.J. (2009) Tumour Flare during Interruption of Temsirolimus Treatment for Metastatic Renal Cell Cancer. Clinical Oncology, 21(9), pp. 732-733. (doi: 10.1016/j.clon.2009.07.006)

Jones, R. J. et al. (2009) Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment, 114(2), pp. 211-221. (doi: 10.1007/s10549-008-9997-1)

Jones, R., Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi: 10.1007/s00280-007-0486-8)

Twelves, C., Trigo, J. M., Jones, R. , De Rosa, F., Rakhit, A., Fettner, S., Wright, T. and Baselga, J. (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. European Journal of Cancer, 44(3), pp. 419-426. (doi: 10.1016/j.ejca.2007.12.011)

Jones, R.J., Boyce, T., Fennell, M., Jacobs, V., Pinto, F., Duffield, E., Clack, G., Green, T., Kelly, J. and Robertson, J. (2008) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology, 61(1), pp. 23-32. (doi: 10.1007/s00280-007-0440-9)

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R., Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi: 10.1158/1078-0432.CCR-06-1627)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi: 10.2174/1874079000701010009)

Glen, H. and Jones, R.J. (2003) 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003. Breast Cancer Research, 5(4), pp. 198-201. (doi: 10.1186/bcr611)

Jones, R. , Avizienyte, E., Wyke, A., Owens, D., Brunton, V. and Frame, M. (2002) Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM1 2C human colorectal cancer cells. British Journal of Cancer, 87(10), pp. 1128-1135. (doi: 10.1038/sj.bjc.6600594)

Avizienyte, E., Wyke, A., Jones, R. , McLean, G., Westhoff, M., Brunton, V. and Frame, M. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nature Cell Biology, 4(8), pp. 632-638. (doi: 10.1038/ncb829)

Jones, R. and Twelves, C. (2002) Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Expert Review of Anticancer Therapy, 2(1), pp. 13-22. (doi: 10.1586/14737140.2.1.13)

Twelves, C. and Jones, R. (2001) Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy, 2(9), pp. 1495-1505. (doi: 10.1517/14656566.2.9.1495)

Book Sections

Jones, R. J. (2018) Neoadjuvant vs. adjuvant chemotherapy: which is right? In: Soria, F. and Gontero, P. (eds.) Treating Urothelial Bladder Cancer. Springer: Cham, pp. 75-81. ISBN 9783319785585 (doi: 10.1007/978-3-319-78559-2_10)

Jones, R. J. (2018) The role of medical oncologist. In: Soria, F. and Gontero, P. (eds.) Treating Urothelial Bladder Cancer. Springer: Cham, pp. 119-122. ISBN 9783319785585 (doi: 10.1007/978-3-319-78559-2_15)

Fulton, B. and Jones, R. J. (2016) Combination treatment strategies with docetaxel in patients with metastatic prostate. In: Balaji, K.C. (ed.) Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Springer: Cham, pp. 93-105. ISBN 9783319313399 (doi: 10.1007/978-3-319-31341-2_7)

Jones, R.J., Green, T.P. and Elvin, P. (2011) Discovery and development of drugs targeting tumour invasion and metastasis. In: Lyden, D., Welch, D.R. and Psaila, B. (eds.) Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press, pp. 600-611. ISBN 9780521887212

Research Reports or Papers

Welisch, G., Keith, N. , Jones, R. and Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. Project Report. OSF. (doi: 10.17605/OSF.IO/243XN).

Welisch, G. et al. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? Project Report. OSF. (doi: 10.17605/OSF.IO/KWHQF).

Conference or Workshop Item

Rana, D. et al. (2020) Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting. EUHEA 2020, Online, 9 July 2020.

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)